Consent discussion draft

Entries stay in this page’s memory and clear on reload. Do not enter names, MRNs or dates of birth. Printing or saving a PDF creates a separate document that must be handled under local policy.

1. Treatment and purpose

Pembrolizumab + pemetrexed + carboplatin · NCCP 00568 v5

All three medicines on Day 1, once every 21 days, for up to four cycles. Your team may adjust the plan. Carboplatin stops. Pembrolizumab and pemetrexed may continue every 21 days while appropriate. Duration and changes are agreed with your oncology team.

Review the treatment journey, tests and phase transitions with the patient.

2. Risks and supportive care

Pembrolizumab · Immunotherapy

The immune system can also inflame healthy organs. New cough, diarrhoea, unusual weakness, severe headache, thirst or a spreading rash need prompt advice. Effects can start during treatment or after it finishes.

Pemetrexed · Chemotherapy

Healthy tissues can be affected too: low blood counts, a sore mouth, rash and kidney problems are important. Folic acid, vitamin B12 and prescribed steroids help reduce particular risks.

Carboplatin · Chemotherapy

Low blood counts, nausea and vomiting can occur. An allergic reaction is also possible: tell the nurse immediately if you feel flushed, itchy, tight-chested or unwell during the drip.

These are selected discussion prompts, not a complete risk list. Discuss serious, potentially life-threatening and lasting effects; tailor the conversation to comorbidities and the patient’s priorities. Discuss expected benefit, alternatives and important short- and longer-term risks. Tell the team about all medicines, existing illnesses, pregnancy possibility and symptoms that matter to you.

3. Understanding and next steps

Consent is a conversation and can be reconsidered. Tick boxes record discussion topics only; they do not establish capacity, consent or authorisation.